The PATHFINDER I Registry is a pilot study to evaluate the safety and efficacy of the Auryon Atherectomy System in the real-world treatment of de novo, re-stenotic, and in-stent restenosis lesions in infrainguinal arteries of patients with Peripheral Artery Diseases.
The first patient has been enrolled in its NanoKnife DIRECT Clinical Study. (NanoKnife® Irreversible Electroporation (IRE) “Data IRE Cancer Treatment” clinical study). The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. The first patient enrollment closely follows the United States Food and Drug Administration’s (FDA) April 1, 2019 approval of AngioDynamics’ investigational device exemption (IDE) application.
AngioDynamics Reported: DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer
AngioDynamics announced that the Company received central Institutional Review Board (IRB) approval to conduct its NanoKnife® Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study (DIRECT).
AngioDynamics to Acquire RadiaDyne and its Revolutionary OARtrac® Radiation Dose Monitoring Platform to Further Expand Oncology Portfolio
RadiaDyne Revolutionary OARtrac® Radiation Dose Monitoring Platform was acquired today by AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced an agreement to acquire RadiaDyne,...
8/15/18: “The addition of the BioSentry technology to our oncology portfolio is the type of strategic and thoughtful acquisition that aligns with our plans to deliver safer, clinically relevant, and economically favorable solutions that improve patient outcomes,” said Jim Clemmer, President and CEO of AngioDynamics. “By expanding our offerings in the oncology discipline, we are creating an opportunity to serve patients who may also benefit from our core products earlier in their disease state.”
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology/surgery, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Solero Microwave Tissue...